Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret? -- Ignore unavailable to you. Want to Upgrade?

To: mesaone who wrote (1291)	4/1/1999 11:36:00 AM
From: Keith Lenart	Read Replies (1) \| Respond to of 1432

I'd be cautious... Just a comment from a casual observer, I don't have shares long or short, but conventional wisdom says to "sell the news" especially in a case such as this where FDA approval was expected and is really not unexpected. Also, from a technical perspective today's gap up was a very nice "pop". However, if the stock doesn't hold at least the 19 3/8 level at the close (January highs), it's likely to fall back down again before making a move higher.

To: mesaone who wrote (1291)	4/1/1999 1:02:00 PM
From: Spider Valdez	Read Replies (2) \| Respond to of 1432

great news! good things come to those who wait! best of luck friend! biz.yahoo.com -- Wednesday March 31, 6:35 pm Eastern Time BioTime Receives FDA Approval to Market Hextend BERKELEY, Calif.--(BW HealthWire)--March 31, 1999--BioTime, Inc. (Nasdaq:BTIM - news) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market Hextend®, the Company's physiologically balanced blood plasma volume expander, for the treatment of hypovolemia. Hypovolemia is a condition often associated with blood loss during surgery or from injury. Hextend® maintains circulatory system fluid volume and oncotic pressure and keeps vital organs perfused during surgery. Hextend®, approved for large-volume use in major surgery, is the only blood plasma volume expander that contains hetastarch, buffer, multiple electrolytes, and glucose. Hextend® is also completely sterile to avoid risk of infection. ''We are gratified that Hextend® has received approval,'' said Dr. Paul Segall, BioTime's chief executive officer. ''We have been working closely with our North American marketing partner, Abbott Laboratories, and preparations for the market launch are moving forward.'' BioTime, headquartered in Berkeley develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions and technology for use in surgery, emergency trauma treatment, the preservation of organs awaiting transplant, and other applications. The matters discussed in this press release include forward-looking statements which are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated. Such risks and uncertainties include but are not limited to BioTime's ability to obtain foreign regulatory approval to market Hextend; competition from products manufactured and sold or being developed by other companies; the price of and demand for Hextend; the Company's ability to negotiate favorable foreign licensing or other manufacturing and marketing agreements for its products; the availability of ingredients used in Hextend; and the availability of reimbursement for the cost of Hextend (and related treatment) from government health administration authorities, private health coverage insurers and other organizations. These and other risk factors are discussed in BioTime's Annual Report on Form 10-K filed with the Securities and Exchange Commission. Contact: BioTime, Inc. Victoria Bellport, 510/845-9535 www.biotimeinc.com